UNSPSC 51111655: Rubitecan

This classification denotes a camptothecin analogue with the molecular formula C20H15N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H19C446XXB, chemically known as 4-ethyl-4-hydroxy-9-nitro-1h-pyrano(3,4:6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione but generally known as rubitecan, which bears US NIH Compound Identifier 123613. European Medicines Agency schedules Rubitecan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33089.

UNSPSC 51111655 Rubitecan is a Commodity code covering a specific pharmaceutical product — a topoisomerase inhibitor used in oncology treatment — that state and local governments procure through their pharmacy benefit programs, health plans, and institutional formularies. State and local buying under this code centers on securing supply agreements, pricing arrangements, and fulfillment capacity for rubitecan dispensing through pharmacy networks, including direct-to-manufacturer contracting models that bypass traditional wholesaler and pharmacy benefit manager channels. The issuing bodies pursuing rubitecan procurement include state health and human services departments managing Medicaid and employee health benefits, state agencies with self-insured health plans, and institutional health systems within state university and corrections systems.

The Texas Health and Human Services Commission posted a Request for Information (RFI) No. HHS0017013 in early April 2026 to explore vendor capabilities for direct-to-manufacturer prescription fulfillment, including rubitecan and other pharmaceuticals, as part of its Therapeutic Pharmacy Initiative. The RFI, with a response deadline of April 3, 2026, sought vendor experience with direct contracting outside traditional pharmacy benefit manager and group purchasing organization arrangements, particularly for self-insured employer and government health plans. The procurement signals a shift toward outcomes-based and value-based pharmaceutical agreements as Texas HHS evaluates future formal solicitation strategy. This represents the primary recent state-local activity identified under the code; geographic concentration and repeat-buyer patterns remain limited in the available record.